Abdelfatah Eihab, Guzzetta Angela A, Nagarajan Neeraja, Wolfgang Christopher L, Pawlik Timothy M, Choti Michael A, Schulick Richard, Montgomery Elizabeth A, Meyer Christian, Thornton Katherine, Herman Joseph, Terezakis Stephanie, Frassica Deborah, Ahuja Nita
Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Surg Oncol. 2016 Jul;114(1):56-64. doi: 10.1002/jso.24256. Epub 2016 Apr 13.
Retroperitoneal sarcomas are connective tissue tumors arising in the retroperitoneum. Surgical resection is the mainstay of treatment. Debate has arisen over extent of resection, changes in histological classification/grading, and interest in incorporating radiotherapy. Therefore, we reviewed our institution's experience to evaluate prognostic factors.
Retrospective chart review of all primary RPS patients at Johns Hopkins Hospital from 1994 to 2010. Histologic diagnosis and grading were re-evaluated with current criteria. Prognostic factors for survival, and recurrence were assessed.
One hundred thirty-one primary RPS patients met inclusion criteria. Median survival for patients who undergo en-bloc resection to negative margins (R0/R1) is 81.7 months. Surgical margins and grade were the most important factors for survival along with age, gender, presence of metastases and resection of ≥5 organs. Five-year survival for R0/R1 resection was 60%, similar to compartmental resection. Radiotherapy significantly decreased local recurrence (P = 0.026) on multivariate analysis. Grade in leiomyosarcomas and dedifferentiation in liposarcomas dictated patterns of local versus distal recurrence.
En bloc surgical resection to R0/R1 margins remains the cornerstone of therapy and provides comparable outcomes to compartmental resections. Grade remains important for prognosis, and histology dictates recurrence patterns. Radiotherapy appears promising for local control and warrants further investigation. J. Surg. Oncol. 2016;114:56-64. © 2016 Wiley Periodicals, Inc.
腹膜后肉瘤是起源于腹膜后的结缔组织肿瘤。手术切除是主要的治疗方法。关于切除范围、组织学分类/分级的变化以及纳入放疗的兴趣已经引发了争论。因此,我们回顾了我们机构的经验以评估预后因素。
对1994年至2010年约翰霍普金斯医院所有原发性腹膜后肉瘤患者进行回顾性病历审查。根据当前标准重新评估组织学诊断和分级。评估生存和复发的预后因素。
131例原发性腹膜后肉瘤患者符合纳入标准。整块切除至阴性切缘(R0/R1)患者的中位生存期为81.7个月。手术切缘和分级是生存的最重要因素,年龄、性别、转移灶的存在以及≥5个器官的切除也是如此。R0/R1切除的5年生存率为60%,与分区切除相似。多因素分析显示放疗显著降低局部复发(P = 0.026)。平滑肌肉瘤的分级和脂肪肉瘤的去分化决定了局部与远处复发的模式。
整块手术切除至R0/R1切缘仍然是治疗的基石,与分区切除的结果相当。分级对预后仍然很重要,组织学决定复发模式。放疗在局部控制方面似乎很有前景,值得进一步研究。《外科肿瘤学杂志》2016年;114:56 - 64。©2016威利期刊公司